202 results

Definition and Prognostic Value of Ph-like and IKZF1plus Status in Children With Down Syndrome and B-cell Precursor Acute Lymphoblastic Leukemia

Palmi, Chiara; Bresolin, Silvia; Junk, Stefanie; More

HemaSphere. 7(6):e892, June 2023.

Prevalence of MGCS Among Patients With Monoclonal Gammopathies

Theodorakakou, Foteini; Fotiou, Despina; Gavriatopoulou, Maria; More

HemaSphere. 7(6):e908, June 2023.

Incidence and Characteristics of Hypersensitivity Reactions to PEG-asparaginase Observed in 6136 Children With Acute Lymphoblastic Leukemia Enrolled in the AIEOP-BFM ALL 2009 Study Protocol

Rizzari, Carmelo; Möricke, Anja; Valsecchi, Maria Grazia; More

HemaSphere. 7(6):e893, June 2023.

Hypersensitivity Reactions to Native E. coli L-asparaginase in Children With Acute Lymphoblastic Leukemia Treated in Trial ALL-BFM 2000: Impact of Treatment Schedule and Type of Glucocorticoid in Induction

Möricke, Anja; Rizzari, Carmelo; Alten, Julia; More

HemaSphere. 7(6):e888, June 2023.

SARS-CoV-2 Infection in Patients With Waldenström’s Macroglobulinemia: A Multicenter International Cohort Study

Defrancesco, Irene; Ferretti, Virginia Valeria; Morel, Pierre; More

HemaSphere. 7(6):e887, June 2023.

High-risk Combinations of Additional Chromosomal Abnormalities in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia: JALSG Ph+ALL TKI-SCT Study

Nishiwaki, Satoshi; Sugiura, Isamu; Fujisawa, Shin; More

HemaSphere. 7(6):e899, June 2023.

Risk Factors of Progression in Low-tumor Burden Follicular Lymphoma Initially Managed by Watch and Wait in the Era of PET and Rituximab

Rodier, Cyrielle; Kanagaratnam, Lukshe; Morland, David; More

HemaSphere. 7(5):e861, May 2023.

NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma

Verkleij, Christie P.M.; Frerichs, Kristine A.; Broekmans, Marloes E.C.; More

HemaSphere. 7(5):e881, May 2023.

Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients With Lymphoproliferative Disorders on BTKi

Zamprogna, Giulia; Frustaci, Anna Maria; Travi, Giovanna; More

HemaSphere. 7(5):e880, May 2023.

Genetic Subtypes and Outcome of Patients Aged 1 to 45 Years Old With Acute Lymphoblastic Leukemia in the NOPHO ALL2008 Trial

Norén-Nyström, Ulrika; Andersen, Mette K.; Barbany, Gisela; More

HemaSphere. 7(5):e883, May 2023.

The Prognostic Effect of IKZF1 Deletions in ETV6::RUNX1 and High Hyperdiploid Childhood Acute Lymphoblastic Leukemia

Østergaard, Anna; Enshaei, Amir; Pieters, Rob; More

HemaSphere. 7(5):e875, May 2023.

Obinutuzumab Can Be Administered as a 90-minute Short Duration Infusion in Patients With Previously Untreated Follicular Lymphoma: GAZELLE End of Induction Analysis

Canales, Miguel A.; Buchholz, Thomas A.; Bortolini, Jaisson A.P.; More

HemaSphere. 7(4):e860, April 2023.

Outcomes of Patients With Classic Hodgkin Lymphoma Who Relapsed After Autologous Stem Cell Transplant

Tun, Aung M.; Wang, Yucai; Matin, Aasiya; More

HemaSphere. 7(4):e869, April 2023.

Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi

Gotti, Manuel; Sciarra, Roberta; Pulsoni, Alessandro; More

HemaSphere. 7(4):e837, April 2023.

A Decision-tree Approach to Stratify DLBCL Risk Based on Stromal and Immune Microenvironment Determinants

Zaccaria, Gian Maria; Vegliante, Maria Carmela; Mezzolla, Giuseppe; More

HemaSphere. 7(4):e862, April 2023.

Genetic and Microenvironment Features Do Not Distinguish Follicular Lymphoma Patients Requiring Immediate or Deferred Treatment

Stevens, Wendy B. C.; Los-de Vries, G. Tjitske; Langois-Jacques, Carole; More

HemaSphere. 7(4):e863, April 2023.

Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive After Treatment for Relapsed Follicular Lymphoma: A Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study

Trotman, Judith; Presgrave, Peter; Carradice, Duncan P.; More

HemaSphere. 7(3):e836, March 2023.

Survival by First-line Treatment Type and Timing of Progression Among Follicular Lymphoma Patients: A National Population-based Study in Sweden

Weibull, Caroline E.; Wästerlid, Tove; Wahlin, Björn Engelbrekt; More

HemaSphere. 7(3):e838, March 2023.

Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients With Relapsed/Refractory Multiple Myeloma: Final Data From the Phase 2 ELOQUENT-3 Trial

Weisel, Katja; Dimopoulos, Meletios A.; San-Miguel, Jesús; More

HemaSphere. 7(3):e843, March 2023.

Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma

Merryman, Reid W.; Michaud, Laure; Redd, Robert; More

HemaSphere. 7(2):e826, February 2023.

Baseline 18F-FDG Metabolic Tumor Volume Predicts Response to Rituximab Induction in Post-transplant Lymphoproliferative Disorders: A Multi-institutional Retrospective Study

Morland, David; Kanagaratnam, Lukshe; Hubelé, Fabrice; More

HemaSphere. 7(2):e833, February 2023.

Cytokine Hyperresponsiveness in Children With ETV6::RUNX1-positive Acute Lymphoblastic Leukemia After Challenge With Common Pathogens

Rüchel, Nadine; Oldenburg, Marina; Janssen, Stefan; More

HemaSphere. 7(2):e835, February 2023.

Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients

Ocio, Enrique M.; Bringhen, Sara; Martinez-Lopez, Joaquin; More

HemaSphere. 7(2):e829, February 2023.

IGH Rearrangement Evolution in Adult KMT2A-rearranged B-cell Precursor ALL: Implications for Cell-of-origin and MRD Monitoring

Darzentas, Franziska; Szczepanowski, Monika; Kotrová, Michaela; More

HemaSphere. 7(1):e820, January 2023.

Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols

Barba, Pere; Morgades, Mireia; Montesinos, Pau; More

HemaSphere. 7(1):e810, January 2023.

Outcome Prediction in Patients With Large B-cell Lymphoma Undergoing Chimeric Antigen Receptor T-cell Therapy

Voltin, Conrad-Amadeus; Gödel, Philipp; Beckmann, Laura; More

HemaSphere. 7(1):e817, January 2023.

Reduced 8-Gray Compared to Standard 12-Gray Total Body Irradiation for Allogeneic Transplantation in First Remission Acute Lymphoblastic Leukemia: A Study of the Acute Leukemia Working Party of the EBMT

Spyridonidis, Alexandros; Labopin, Myriam; Savani, Bipin; More

HemaSphere. 7(1):e812, January 2023.

SARS-CoV-2 Infection Incidence and Outcome Before and After Full Vaccination in Patients With Monoclonal Gammopathy of Undetermined Significance

Sgherza, Nicola; Di Gennaro, Daniela; Curci, Paola; More

HemaSphere. 6(12):e800, December 2022.

Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy

Argnani, Lisa; Broccoli, Alessandro; Pellegrini, Cinzia; More

HemaSphere. 6(12):e798, December 2022.

Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results

Ghia, Paolo; Pluta, Andrzej; Wach, Małgorzata; More

HemaSphere. 6(12):e801, December 2022.

Efficacy and Safety of Obinutuzumab-chemotherapy Combinations in Front-line Treatment of Follicular Non-Hodgkin Lymphoma During the COVID-19 Pandemic: A Study of KROHEM, the Croatian Cooperative Group for Hematologic Diseases

Galusic, Davor; Basic-Kinda, Sandra; Pijuk, Andela; More

HemaSphere. 6(12):e807, December 2022.

Distinct Immunogenetic Profiles of Chronic Lymphocytic Leukemia in Asia: A Taiwan Cooperative Oncology Group Registry Study

Yao, Chi-Yuan; Agathangelidis, Andreas; Chuang, Shih-Sung; More

HemaSphere. 6(12):e803, December 2022.

First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA Trial

Braulke, Friederike; Zettl, Florian; Ziepert, Marita; More

HemaSphere. 6(12):e808, December 2022.

CNS Involvement at Initial Diagnosis and Risk of Relapse After Allogeneic HCT for Acute Lymphoblastic Leukemia in First Complete Remission

Kharfan-Dabaja, Mohamed A.; Labopin, Myriam; Bazarbachi, Ali; More

HemaSphere. 6(11):e788, November 2022.

Haploidentical Versus Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Nagler, Arnon; Labopin, Myriam; Swoboda, Ryszard; More

HemaSphere. 6(11):e790, November 2022.

Mineralocorticoid Receptor Pathway Is a Key Mediator of Carfilzomib-induced Nephrotoxicity: Preventive Role of Eplerenone

Efentakis, Panagiotis; Lamprou, Sofia; Makridakis, Manousos; More

HemaSphere. 6(11):e791, November 2022.

A Novel t(5;7)(q31;q21)/CDK6::IL3 in Immature T-cell Acute Lymphoblastic Leukemia With IL3 Expression and Eosinophilia

Pierini, Valentina; Bardelli, Valentina; Giglio, Fabio; More

HemaSphere. 6(11):e795, November 2022.

Improved Clinical Outcome of COVID-19 in Hematologic Malignancy Patients Receiving a Fourth Dose of Anti-SARS-CoV-2 Vaccine: An EPICOVIDEHA Report

Salmanton-García, Jon; Marchesi, Francesco; Glenthøj, Andreas; More

HemaSphere. 6(11):e789, November 2022.

Immune Biomarkers in the Peripheral Blood and Tumor Microenvironment of Classical Hodgkin Lymphoma Patients in Relation to Tumor Burden and Response to Treatment

Mulder, Tom A.; Andersson, Maria L.; Peña-Pérez, Lucía; More

HemaSphere. 6(11):e794, November 2022.

Chimeric Antigen Receptor T-cell Therapy: Imaging Response Criteria and Relation to Progression-free and Overall Survival

Winkelmann, Michael; Rejeski, Kai; Blumenberg, Viktoria; More

HemaSphere. 6(10):e781, October 2022.

Clinical and Prognostic Impact of Copy Number Alterations and Associated Risk Profiles in a Cohort of Pediatric B-cell Precursor Acute Lymphoblastic Leukemia Cases Treated Under ICiCLe Protocol

Gupta, Sanjeev Kumar; Singh, Minu; Chandrashekar, Pragna H.; More

HemaSphere. 6(10):e782, October 2022.

Duplex Sequencing Uncovers Recurrent Low-frequency Cancer-associated Mutations in Infant and Childhood KMT2A-rearranged Acute Leukemia

Pilheden, Mattias; Ahlgren, Louise; Hyrenius-Wittsten, Axel; More

HemaSphere. 6(10):e785, October 2022.

Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma

Sonneveld, Pieter; Zweegman, Sonja; Cavo, Michele; More

HemaSphere. 6(10):e786, October 2022.

Molecular Cytogenetic Profiling Reveals Similarities and Differences Between Localized Nodal and Systemic Follicular Lymphomas

Horn, Heike; Jurinovic, Vindi; Leich, Ellen; More

HemaSphere. 6(9):e767, September 2022.

Preclinical Evidence for the Efficacy of CD79b Immunotherapy in B-cell Precursor Acute Lymphoblastic Leukemia

Lenk, Lennart; Winterberg, Dorothee; Vogiatzi, Fotini; More

HemaSphere. 6(8):e754, August 2022.

Second Booster BNT162b2 Restores SARS-CoV-2 Humoral Response in Patients With Multiple Myeloma, Excluding Those Under Anti-BCMA Therapy

Ntanasis-Stathopoulos, Ioannis; Karalis, Vangelis; Gavriatopoulou, Maria; More

HemaSphere. 6(8):e764, August 2022.

Five Percent Variant Allele Frequency Is a Reliable Reporting Threshold for TP53 Variants Detected by Next Generation Sequencing in Chronic Lymphocytic Leukemia in the Clinical Setting

Pandzic, Tatjana; Ladenvall, Claes; Engvall, Marie; More

HemaSphere. 6(8):e761, August 2022.

A Retrospective Cohort Study of Treatment Outcomes of Adult Patients With Relapsed or Refractory Follicular Lymphoma (ReCORD-FL)

Salles, Gilles; Schuster, Stephen J.; Fischer, Luca; More

HemaSphere. 6(7):e745, July 2022.

Blood-based Monitoring of Relapsed/Refractory Hodgkin Lymphoma Patients Predict Responses to Anti-PD-1 Treatment

Drees, Esther E. E.; Jauw, Yvonne W. S.; van Dijk, Erik; More

HemaSphere. 6(7):e749, July 2022.

Therapy-related Myeloid Neoplasms in Patients With Chronic Lymphocytic Leukemia Who Received FCR/FC as Frontline Therapy

Laribi, Kamel; Baugier de Materre, Alix; Ghez, David; More

HemaSphere. 6(6):e716, June 2022.

Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia

Kutsch, Nadine; Pallasch, Christian; Decker, Thomas; More

HemaSphere. 6(6):e729, June 2022.

Efficacy of Isatuximab With Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of a UK-Wide Real-World Dataset

Djebbari, Faouzi; Rampotas, Alexandros; Vallance, Grant; More

HemaSphere. 6(6):e738, June 2022.

Outcome of COVID-19 in Patients With Mantle Cell Lymphoma—Report From the European MCL Registry

Tilch, Marie-Kristin; Visco, Carlo; Kinda, Sandra; More

HemaSphere. 6(5):e0711, May 2022.

Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia

Kutsch, Nadine; Pallasch, Christian; Tausch, Eugen; More

HemaSphere. 6(4):e692, April 2022.

Monitoring of Leukemia Clones in B-cell Acute Lymphoblastic Leukemia at Diagnosis and During Treatment by Single-cell DNA Amplicon Sequencing

Meyers, Sarah; Alberti-Servera, Llucia; Gielen, Olga; More

HemaSphere. 6(4):e700, April 2022.

Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations

Baliakas, Panagiotis; Espinet, Blanca; Mellink, Clemens; More

HemaSphere. 6(4):e707, April 2022.

Prognostic Stratification of Diffuse Large B-cell Lymphoma Using Clinico-genomic Models: Validation and Improvement of the LymForest-25 Model

Mosquera Orgueira, Adrián; Díaz Arías, Jose Ángel; Cid López, Miguel; More

HemaSphere. 6(4):e706, April 2022.

Serologic Responses to COVID-19 Vaccines in Hematological Patients Are Predominantly Impaired in Lymphoid but not in Myeloid Malignancies

Petzer, Verena; Steiner, Normann; Angelova-Unterberger, Olga; More

HemaSphere. 6(3):e686, March 2022.

Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial

Herold, Michael; Hoster, Eva; Janssens, Ann; More

HemaSphere. 6(3):e699, March 2022.

The Peptide–Drug Conjugate Melflufen Modulates the Unfolded Protein Response of Multiple Myeloma and Amyloidogenic Plasma Cells and Induces Cell Death

Flanagan, Ken; Kumari, Romika; Miettinen, Juho J.; More

HemaSphere. 6(3):e687, March 2022.

Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma

Houot, Roch; Poeschel, Viola; Altmann, Bettina; More

HemaSphere. 6(2):e672, February 2022.